ArticleDiscover oncology2025
Network pharmacology unveils the intricate molecular landscape of Chrysin in breast cancer therapeutics.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nutritional Impact on Breast Cancer in Menopausal and Post-Menopausal Patients Treated with Aromatase Inhibitors.Cancers · 2025Review
- Chrysin: A Comprehensive Review of Its Pharmacological Properties and Therapeutic Potential.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Chrysin is one of the natural flavonoid compounds Sourced from various plant source, mainly in propolis and honey, demonstrates effective Cancer-suppressing properties, particularly in Breast cancer (BC). However, the specific molecular mechanisms underlying its efficacy in breast cancer treatment have remained elusive. This study employed network pharmacology combined with a molecular docking approach to uncover the intricate details of Chrysin's impact on breast cancer. Utilizing databases such as GeneCards, and disgenet, Pharmmapper, ctd database, Chrysin and potential breast cancer targets were meticulously curated. Through a strategic process of mapping and screening, core targets essential for Chrysin's efficacy in breast cancer treatment were identified. Further refinement through Venn diagram analysis, considering 1350 breast cancer target genes and 433 Chrysin-related targets, identified 140 intersection targets. Subsequent construction of protein-protein interaction networks of 140 intersecting using the STRING and Cytoscape software highlighted these ten targets as core candidates. Functional annotation and pathway analysis, performed using the ShinyGO database, unveiled that the key targets were significantly associated with the Prostate cancer pathways and IL17 signaling pathways. Molecular docking results underscored Chrysin's effective binding to these ten key targets, forming stable protein-ligand complexes. Molecular docking analyses were then conducted to evaluate the impact of Chrysin in the key targets, revealing TP53, JUN, HIF1A, ALB, CASP3, STAT3, BCL2, TNF, AKT1, and IL6 as pivotal players. In summary, this investigation provides valuable revelations into the essential targets and molecular processes through which Chrysin exerts its anti-breast cancer effects. These findings not only enhance our understanding of Chrysin's pharmacological actions in breast cancer but also lay a theoretical groundwork for future investigations into the therapeutic mechanisms of Chrysin in this context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.